FGF19 and metabolic dysfunction-associated steatohepatitis: Fibroblast growth factor 19 (FGF19), secreted by the intestines during feeding, is a signaling hormone downstream of FXR activation and is currently under clinical investigation for the potential treatment of NASH and its associated fibrosis (80).